Alto Neuroscience, Inc (ANRO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Alto Neuroscience, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Alto Neuroscience, Inc (ANRO) has returned 26.29% so far this year and 940.74% over the past 12 months.

Based on dividend-adjusted daily data since Feb 2, 2024, ANRO's average daily return is +0.31%, while the average monthly return is +8.38%. At this rate, your investment would double in approximately 0.7 years.

Historically, 54% of months were positive and 46% were negative. The best month was Oct 2025 with a return of +253.0%, while the worst month was Oct 2024 at -66.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 2 months.

On a daily basis, ANRO closed higher 52% of trading days. The best single day was Oct 20, 2025 with a return of +80.9%, while the worst single day was Oct 23, 2024 at -70.0%.

Alto Neuroscience, Inc has an annualized alpha of 87.59%, beta of 1.15, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 05, 2024.

• This stock participated in 293.12% of S&P 500 Index downside but only 284.87% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ANRO ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Alto Neuroscience, Inc (ANRO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Alto Neuroscience, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alto Neuroscience, Inc was 91.74%, occurring on Apr 4, 2025. Recovery took 231 trading sessions.

The current Alto Neuroscience, Inc drawdown is 7.45%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Alto Neuroscience, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Alto Neuroscience, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.